Print

Lay Description

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

Category

  • Dementia / Alzheimers
  • Nervous System
  • Behaviors and Mental Disorders
  • Aging and Geriatric
IRB Number
20220198HU
NCT Number
NCT05590637

Eligibility

Eligible Ages
18+
Eligible Genders
male and female
Accepts Healthy Volunteers
No

Inclusion Criteria

diagnosed with hallucinations due to Parkinson's disease or dementia with Lewy bodies

Exclusion Criteria

currently taking an antipsychotic medication

Study Design

Arm Groups

Study Contact

Victoria Carranza
210-450-8907
carranzav@uthscsa.edu

Omalys Biggs Rodriguez
210-450-8456
biggsrodrigu@uthscsa.edu

Sarah Martinez
210-450-0569
martinezs23@uthscsa.edu

Carolyn Paiz
210-450-8830
paizc@uthscsa.edu

Charlotte Rhodes
210-450-8454
rhodesc1@uthscsa.edu

Carolyn Paiz
210-450-8830
paizc@uthscsa.edu

Principal Investigator
Sarah Horn